Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Summary

EGFR-TKI has firmly established itself as a first-line treatment for advanced lung cancer with EGFR-sensitive mutations, and the ADAURA study has added to its indications for use as postoperative adjuvant therapy in early- and mid-stage lung cancer.However, clinical data on neoadjuvant EGFR-TKI therapy are still incomplete. A phase II clinical study, CTONG1103, currently ongoing, comparing the efficacy of the first generational EGFR-TKI erlotinib and gemcitabine combined with cisplatin as neoadjuvant therapy for stage IIIA-N2 EGFR mutation-positive non-small-cell lung cancer, did not yield significantly positive objective remission rate (ORR) results. Furmonertinib is a third-generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets Epidermal Growth Factor Receptor (EGFR) mutations.Furmonertinib demonstrates definite efficacy and favorable safety in first-line EGFR-sensitive mutations and EGFR T790M Mutations in second-line and late-line treatment of advanced NSCLC.The aim of this study was to explore the efficacy and safety of furmonertinib neoadjuvant therapy for resectable stage II-IIIB EGFR-sensitive mutant non-small cell lung cancer efficacy and safety. Patinents are planned to be recruited from five centers in China. Eligible patients will receive furmonertinib neoadjuvant therapy for 8 weeks to evaluate the efficacy and safety of furmonnertinib neoadjuvant.

Eligibility

Inclusion Criteria:

* 1）Provide informed consent prior to any study specific procedures
* 2）at least 18 years of age，not more than 75 years
* 3）Histology or cytology diagnose of non-small cell lung cancer within 60 days
* 4）ECOG PS of 0 to 1 at screening with no clinically significant deterioration in the previous 2 weeks
* 5）Stage II-IIIB NSCLC that is expected to be resectable, as assessed by the investigator (8 thUICCTNM staging), with stage IIIB only including cT3N2M0 patients
* 6）According to RECIST 1.1, patients have at least one measureable tumor lesion (The longest axis ≥10mm)
* 7）EGFR mutation positive (exon 19 deletions or exon 21 L858R, with or without other EGFR mutations)
* 8）Without prior anti-tumor treatment
* 9\) Withe adequate organ function of hematology, liver and kidney
* 10）Using adequate and effective contraception, Male patients should be use condoms; women should refrain from breastfeeding and have a negative pregnancy test prior to the first administration of the study drug if within during child-bearing age

Exclusion Criteria:

* 1）Dual or multiple primary NSCLC
* 2）Any prior anti-tumor treatment
* 3）With history of other malignancy except for radical resected tumors without recurrence for 5 years or more
* 4）History of interstitial lung disease or with relative risk factors
* 5）Diseases or clinical states with severe abnormalities of gastrointestinal function that may interfere with the ingestion, transit, or absorption of the study drug.e.g., inability to take medication orally, uncontrolled nausea and vomiting
* 6）Use of strong CYP3A4 inhibitors within 7 days or strong CYP3A4 inducers within 21 days before enrolment; use of traditional Chinese medicine with anti-tumor effect within 21 days before enrolment
* 7）With severe or uncontrolled systemic disease such as uncontrolled hypertention, diabetes mellitus, chronic heart failure, unstable angina, myocardial infarction within 1 year, active hemorrhage, active HBV/HCV/HIV or other infections requiring infusion treatment
* 8）Prolongation of ECG QTc or with relative risk factors
* 9）psychopath and/or mental illness
* 10）Pre-existing or coexisting bleeding disorders
* 11）Women with pregnancy or breastfeeding
* 12）Allergic to study drugs or any component
* 13）Other conditions that, in the opinion of the investigator, make participation in this trial inappropriate

Conditions3

Interventions1

Related trials

• A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer — Minghui Pharmaceutical (Hangzhou) Ltd
• A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
• Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis — Henan Cancer Hospital
• Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations — Peking Union Medical College Hospital
• Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases — Tianjin Medical University Cancer Institute and Hospital
• Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA — Sun Yat-sen University
• High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases — Hunan Province Tumor Hospital
• High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib — Changhai Hospital

Browse More Trials